HCPCS Code Descriptor:
Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
Oncology Biosimilar Colony Stimulating Factor
Route of Administration:
FULPHILA is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Mylan and administered via the Subcutaneous route of administration. The Q Code: Q5108 is aligned to the drug FULPHILA.
Fulphila (pegfilgrastim) is used to prevent patients from developing a deficiency of certain white blood cells by aiding in the production of these white blood cells. This medication is manufactured by Mylan Institutional and is a biosimilar to the drug Neulasta (J2506). Patient assistance programs for this medication can be found through the Viatris Patient Assistance program.
Access Pricing and More By Registering
HCPCS Added Date:
HCPCS Effective Date:
HCPCS Short Description:
Billing and Coding Guide: